Bioqual AI Stock Analysis
Want to see BIOQ full AI Analyst Report?
Bioqual (BIOQ) AI Stock Analysis
Bioqual
(Other OTC:BIOQ)
The overall score is deeply bearish, driven primarily by a severe and accelerating deterioration in financial performance. The company has shifted from profitability to significant losses, taken on an unsustainable debt load, and is now burning cash. This fundamental weakness is confirmed by a bearish technical trend, with the stock trading below all major moving averages. The negative P/E ratio further underscores the lack of earnings power. The combination of a collapsing business model and high leverage presents a critical risk profile.
Bioqual (BIOQ) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $27.73M
- Dividend Yield
- ―
- Average Volume (3M)
- 557
- Price to Earnings (P/E)
- -6.3
- Beta (1Y)
- -0.19
- Revenue Growth
- -14.30%
- EPS Growth
- -610.16%
- Country
- US
- Employees
- 278
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Bioqual Business Overview & Revenue Model
Company Description
Bioqual, Inc. delivers a range of preclinical research solutions, encompassing both in-vivo and in-vitro methodologies, to its diverse clientele of commercial enterprises and government agencies across the United States. Their expertise spans numerou...
Bioqual Financial Statement Overview
Summary
Financial performance is critically weak. Revenue has declined nearly 40% from FY2022 to TTM, gross margin has collapsed to 3.6%, and the company is generating significant net losses (-$4.4M TTM). The balance sheet shows a dangerous surge in debt-to-equity to 1.01, and operating cash flow has turned negative. The overall trend indicates a fundamental breakdown in the business model and a potential solvency crisis.
Income Statement
8Very NegativeBalance Sheet
18Very NegativeCash Flow
5Very Negative| Breakdown | TTM | Aug 2025 | Aug 2024 | Aug 2023 | May 2023 | Aug 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.24M | 39.95M | 48.87M | 58.59M | 62.66M | 66.15M |
| Gross Profit | 1.05M | 1.43M | -1.90M | 7.43M | 12.60M | 13.01M |
| EBITDA | -1.56M | -2.25M | 473.97K | 3.03M | 6.97M | 14.76M |
| Net Income | -4.41M | -4.17M | -1.05M | 483.48K | 835.55K | 5.26M |
Balance Sheet | ||||||
| Total Assets | 67.41M | 68.44M | 57.12M | 56.59M | 61.32M | 63.34M |
| Cash, Cash Equivalents and Short-Term Investments | 16.47M | 16.01M | 17.85M | 15.59M | 7.28M | 2.18M |
| Total Debt | 31.92M | 32.71M | 16.54M | 3.59M | 18.61M | 18.72M |
| Total Liabilities | 35.46M | 36.04M | 20.96M | 18.94M | 23.70M | 25.67M |
| Stockholders Equity | 31.95M | 32.41M | 36.15M | 37.65M | 37.61M | 37.67M |
Cash Flow | ||||||
| Free Cash Flow | -650.68K | -66.78K | 2.71M | 8.76M | 5.99M | -4.57M |
| Operating Cash Flow | -165.45K | 351.44K | 2.94M | 9.36M | 8.23M | 313.36K |
| Investing Cash Flow | -7.46M | -7.08M | -238.78K | -597.13K | -2.24M | -4.73M |
| Financing Cash Flow | 0 | 0 | -447.21K | -447.21K | -894.42K | -1.12M |
Bioqual Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOQ, the sentiment is Negative. The current price of 30.25 is below the 20-day moving average (MA) of 30.76, below the 50-day MA of 32.55, and below the 200-day MA of 34.50, indicating a bearish trend. The MACD of -0.74 indicates Negative momentum. The RSI at 24.49 is Positive, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIOQ.
Bioqual Peers Comparison
Overall Rating
PRPO65Neutral
BDSX44Neutral
VNRX44Neutral
BNGO42Neutral
BIOQ38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 65Neutral | $34.37M | -31.63 | -7.84% | ― | 21.76% | 22.97% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | $98.47M | -3.24 | -442.34% | ― | 31.23% | 48.56% | |
| 44Neutral | $6.81M | -0.06 | 77.30% | ― | 134.01% | 32.90% | |
| 42Neutral | $13.31M | -0.36 | -85.00% | ― | 8.23% | 82.76% | |
| 38Underperform | $27.04M | -6.29 | -13.07% | ― | -14.30% | -610.16% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BIOQ | Bioqual | 30.25 | -8.26 | -21.45% | |
| VNRX | VolitionRX Ltd. | 0.19 | -6.37 | -97.13% | |
| PRPO | Precipio | 19.17 | -7.08 | -26.97% | |
| BNGO | Bionano Genomics | 0.95 | -0.59 | -38.18% | |
| BDSX | Biodesix, Inc. | 8.88 | 1.98 | 28.70% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026
